Chi­nese in­vestors wa­ger $105M on an IPO-bound biotech look­ing to push RNAi as main­stream can­cer ther­a­py

Short­ly af­ter Sir­naomics brought in a $47 mil­lion Se­ries C for its small in­ter­fer­ing RNA pipeline last year, Patrick Lu — the founder, pres­i­dent and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.